Cargando…

Disease exacerbation after rituximab induction in neuromyelitis optica

Detalles Bibliográficos
Autores principales:	Perumal, Jai S., Kister, Ilya, Howard, Jonathan, Herbert, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335814/ https://www.ncbi.nlm.nih.gov/pubmed/25738163 http://dx.doi.org/10.1212/NXI.0000000000000061

Ejemplares similares

Mortality in neuromyelitis optica is strongly associated with African ancestry
por: Mealy, Maureen A., et al.
Publicado: (2018)

Rituximab during pregnancy in neuromyelitis optica: A case report
por: Miranda-Acuña, Jahir, et al.
Publicado: (2019)

Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica
por: Kister, Ilya, et al.
Publicado: (2013)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Schanda, Kathrin, et al.
Publicado: (2015)

Longitudinally extensive myelitis in MS mimicking neuromyelitis optica
por: Whittam, Daniel, et al.
Publicado: (2017)

Neuromyelitis optica spectrum disorder in a patient with Kikuchi-Fujimoto disease
por: Kaku, Michelle, et al.
Publicado: (2016)

Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015)

Neuromyelitis optica phenotype associated with therapy-responsive acute peripheral neuropathy
por: Feyissa, Anteneh M., et al.
Publicado: (2015)

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Periventricular Lesions Help Differentiate Neuromyelitis Optica Spectrum Disorders from Multiple Sclerosis
por: Raz, Eytan, et al.
Publicado: (2014)

Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
por: Gao, Fulin, et al.
Publicado: (2019)

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
por: Etemadifar, Masoud, et al.
Publicado: (2017)

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience
por: Jade, Jui Dilip, et al.
Publicado: (2017)

Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
por: Farhat, Lara, et al.
Publicado: (2018)

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
por: Nosadini, Margherita, et al.
Publicado: (2016)

Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
por: Fan, Xueli, et al.
Publicado: (2016)

Interferon Alpha Association with Neuromyelitis Optica
por: Asgari, Nasrin, et al.
Publicado: (2013)

Neuromyelitis optica with fluorosis: An association or coincidence
por: Arshad, Faheem, et al.
Publicado: (2020)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis
por: Zhao, Shuo, et al.
Publicado: (2021)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions
por: Ventura, Rachel E., et al.
Publicado: (2016)

MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T
por: Sinnecker, Tim, et al.
Publicado: (2016)

Neuromyelitis Optica Spectrum Disorder Associated with Cervical Spondylosis
por: Zhou, Yuan, et al.
Publicado: (2015)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

Increased Circulating T Follicular Helper Cells Are Inhibited by Rituximab in Neuromyelitis Optica Spectrum Disorder
por: Zhao, Cong, et al.
Publicado: (2017)

Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
por: Yang, Yang, et al.
Publicado: (2021)

Rheumatoid arthritis with aquaporin-4 antibody-positive neuromyelitis optica receiving rituximab therapy
por: Reen Wang, Chrong, et al.
Publicado: (2021)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Neuromyelitis optica and neuroregeneration
Publicado: (2012)

Immunotherapy of Neuromyelitis Optica
por: Bienia, Benjamin, et al.
Publicado: (2013)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

Effective treatment of CLIPPERS with long-term use of rituximab
por: Cipriani, Veronica P., et al.
Publicado: (2018)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico
por: Zarei, Sara, et al.
Publicado: (2018)

Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
por: Wang, Hao, et al.
Publicado: (2021)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u7ree8jpfgrsd3p6dv7oki8sgn